Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Crinetics Pharmaceuticals's Revenue for the
three
months ended in Jun. 2026 was €21.80 Mil. Crinetics Pharmaceuticals's average Accounts Receivable for the
three
months ended in Jun. 2026 was €7.65 Mil.
Hence, Crinetics Pharmaceuticals's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.85.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Crinetics Pharmaceuticals Receivables Turnover Related Terms
Crinetics Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Z4 vs SYRE, PTGX, PRAX: Receivables Turnover Comparison
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals (FRA:6Z4) has a Receivables Turnover of 2.85 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Crinetics Pharmaceuticals and its competitors. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #296 out of 841 companies in the Biotechnology industry, placing it in the top 35.2%.
Is Crinetics Pharmaceuticals' Receivables Turnover too high?
Crinetics Pharmaceuticals' current Receivables Turnover is 2.85. The Biotechnology industry median Receivables Turnover is 5.27. Crinetics Pharmaceuticals' value of 2.85 is 45.9% below this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #296 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Crinetics Pharmaceuticals has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Receivables Turnover compare to SYRE and PTGX?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #296 out of 841 companies for Receivables Turnover. This puts Crinetics Pharmaceuticals in the upper half of its industry. The industry median Receivables Turnover is 5.27. Crinetics Pharmaceuticals' value of 2.85 is 45.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Receivables Turnover of 2.85 is 45.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Receivables Turnover is 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (FRA:6Z4) is currently considered Possible Value Trap. The stock's GF Value™ is €797.28, compared to a current price of €71.34 — trading 91.1% below its estimated fair value. The current Receivables Turnover is 2.85 and 45.9% below the Biotechnology industry median of 5.27. Crinetics Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Crinetics Pharmaceuticals (FRA:6Z4), the current Receivables Turnover is 2.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of €71.34 is trading 91.1% below its estimated GF Value™ of €797.28.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:6Z4:
Receivables Turnover: 2.85
GF Value™: €797.28 vs. price of €71.34 (91.1% below fair value)
Industry Position: 45.9% below the Biotechnology median (#296 of 841)
No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
35GF Score
Get the complete analysis for FRA:6Z4
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Z4 has been successfully added to your 
